Debiopharm Group is a privately-owned Swiss-based pharmaceutical company founded in 1979. They specialize in drug development from clinical research through marketing. They have over 300 staff and 400 partners worldwide. Debiopharm has commercialized several cancer drugs generating billions in sales. Their business model bridges academic research and biotech startups to fully fund drug development and approval. They are looking to partner on small molecules, biologics, and siRNAs focused on oncology, infection, and immunology. Debiopharm conducts formulation, manufacturing and has FDA and Swissmedic approved facilities.

1. Debiopharm Group™
Bridging discovery to market
© Debiopharm Group™ 2012

2. Debiopharm Group™
 Key expertise : drug development
 Founded in 1979, privately-owned, financially independent
 Based in Switzerland
 Lausanne (Headquarters)  Martigny  Swiss Technology
 Worldwide scouting  Applied research Institute
 Drug development  Formulation  R&D unit
 Biotech investment  GMP manufacturing  Bioanalytics
 Financial management
 Team : staff over 300
 Extensive international network of partners: over 400
2 © Debiopharm Group™ 2012

3. Debiopharm Group’s achievements
 Five products commercialised worldwide
Several Billion dollar sales (turnover ~ $ 2.7 B)
 Eloxatin® / Elplat® / Dacotin® / Dacplat®
 Decapeptyl® / Trelstar® / Pamorelin® 1-month
 Decapeptyl® / Trelstar® / Pamorelin® 3-month
 Decapeptyl® / Trelstar® 6-month
 Moapar® / Salvacyl® 3-month
3 © Debiopharm Group™ 2012

4. Four strategic priorities
:: Development of molecules
:: Redesign of molecules, innovative
formulations & peptide chemistry
Debiopharm
:: Companion diagnostics
Group & personalised medicine
:: Access to medicines
in emerging economies
4 © Debiopharm Group™ 2012

5. Business model: a bridge to develop therapies
Discovery DEBIOPHARM GROUP™ Market
Fully funded
Academic institutions drug development Pharma
Biotech & innovation
Start-up
Pharma
from molecule rapid and creative development to drug approval
5 © Debiopharm Group™ 2012

6. Main International Partners: Licensors…
 USA  China  India  Japan
 Ascenta Therapeutics  Press release  Aurigene  Nagoya City
soon University
 Curis
 Mercury Therapeutics Inc.
 MSM Protein Technologies
 Tulane University
 Yale University
…all over the world
6 © Debiopharm Group™ 2012

7. Main International Partners: Licensees…
 Sanofi
 Novartis
 Pfizer Inc.
 Watson Pharmaceuticals
 Yakult
 Ipsen
 Aché
 Dr. Reddy’s Laboratories
 Ferring
 Tecnofarma
…covering the entire world
7 © Debiopharm Group™ 2012

8. What we are looking for
 Small molecules  Therapeutic areas
 Biologics:  Oncology: innovative targets
 Peptides  Selected indications:
 Infection
 Proteins
 Metabolism
 siRNAs  Immunology
8 © Debiopharm Group™ 2012

9. GMP Manufacturing, Formulation and Fill & Finish
 Formulation
 Redesign of molecules (Debio025 / anti-HCV)
 Peptide chemistry
 Innovative formulations: oral delivery, SR (PLGA-based)
 Drug vials
 Bulk manufacturing
 Distributed worldwide
 Facilities
 FDA & Swissmedic inspected
9 © Debiopharm Group™ 2012

10. Debiopharm Group™ Pipeline
Preclinical
Submitted
Phase III
Phase II
Phase I
Debio 025 - HCV,Cyclophilin inhibitor (worldwide licence to Novartis except JPN)
Debio 8206 CPP - TRI 6M, Central Precocious Puberty
Debio 8206 SC - TRI 6M, GnrH agonist, Prostate cancer
Debio 0932 - Oncology, Hsp90 inhibitor
Debio 1143 - Oncology, SMAC mimetic (pro-apoptotic)
Debio 025 - HCV,Cyclophilin inhibitor, Japan
yDebio 1036 - Autoimmune diseases, undisclosed target
yDebio 0617 - Oncology, undisclosed target
Debio 0930 - Metabolic diseases, AMPK activator
yy
Debio 0929 - Oncology, undisclosed target
Debio 0826 - Oncology, undisclosed target
Debio 1141 - Urothelial carcinoma, siRNA
10 Debio 1142 - Oncology, undisclosed target © Debiopharm Group™ 2012

11. 10 reasons to partner with Debiopharm Group
1. Financial strength and independence
2. Creativity, adaptability, flexibility
3. Full development expertise: preclinical, clinical, formulation
& Life Cycle Management, etc.
4. Entrepreneurial and start-up mindset
5. Stable top management
6. Rapid decision-making
7. Long term vision
8. Strong & long-lasting partnerships
9. Risk mitigation strategies: out-licensing at phase II / Phase III
10. Discoverer benefits from the financial success
11 © Debiopharm Group™ 2012

12. Debiopharm Group’s team builds the future
Richard Juilliart - 2010
12 © Debiopharm Group™ 2012

13. Contact us
Debiopharm Group™ Headquarters
Forum “après-demain”
Chemin Messidor 5-7
CP 5911, CH - 1002 Lausanne
Switzerland
Tel. +41 (0)21 321 01 11
Fax +41 (0)21 321 01 69
www.debiopharm.com
Photo: Jacques Straesslé
Maurice Wagner
Director Corporate Affairs & Communication
mwagner@debiopharm.com
13 © Debiopharm Group™ 2012